TABLE 1.
Strain | Phenotype | Time (day p.i.) when penicillin treatment was startedb | No. of animals with diffuse hypercellularity at following percentilea:
|
||
---|---|---|---|---|---|
60th | 70th | 80th | |||
NZAN0 | Ska1− Emr Kanr | 7 | 6/15 | 3/15 | 1/15 |
NZAN5 | Ska1− Emr Kanr Skc5+ | 7 | 6/25 | 2/25 | 0/25 |
NZAN0 | Ska1− Emr Kanr | 16 | 2/14 | 2/14 | 0/14 |
NZAN5 | Ska1− Emr Kanr Skc5+ | 16 | 5/16 | 2/16 | 0/16 |
NZAN1 | Ska1− Emr Kanr Ska1+ | 16 | 18/36*** | 9/36*** | 2/36 |
Uninfected mice | |||||
NZAN0 and NZAN5 controlsc | 7/23 | 3/23 | 0/23 | ||
NZAN1 controlsd | 0/10 | 0/10 | 0/10 |
Corresponds to a value below which the designated percentage of the total calculated glomeruli of the uninfected control group is found. We defined diffuse hypercellularity when more than 50% of the glomeruli analyzed in a mouse displayed cell numbers above that of the percentile of the uninfected control mice in the same experiment. Data are given as the number with diffuse hypercellularity/total number tested. ∗, P < 0.05; ∗∗, P < 0.01; ∗∗∗, P < 0.001 (degree of significance for the occurrence of diffuse hypercellularity, compared to the uninfected controls in the same experiment).
All animals were sacrificed on day 21 p.i.
Uninfected mice belonging to the same experiment as NZAN0- and NZAN5-infected mice.
Uninfected mice belonging to the same experiment as NZAN1-infected mice.